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Frontiers in Immunology | wwwGroup B Streptococcus (GBS) is a common intestinal colonizer during the neonatal period, but also
may cause late-onset sepsis or meningitis in up to 0.5% of otherwise healthy colonized infants after
day 3 of life. Transmission routes and risk factors of this late-onset form of invasive GBS disease
(iGBS) are not fully understood. Cases of iGBS with recurrence (n=25) and those occurring in
parallel in twins/triplets (n=32) from the UK and Ireland (national surveillance study 2014/15) and
from Germany and Switzerland (retrospective case collection) were analyzed to unravel shared (in
affected multiples) or fixed (in recurrent disease) risk factors for GBS disease. The risk of iGBS
among infants from multiple births was high (17%), if one infant had already developed GBS
disease. The interval of onset of iGBS between siblings was 4.5 days and in recurrent cases 12.5
days. Disturbances of the individual microbiome, including persistence of infectious foci are
suggested e.g. by high usage of perinatal antibiotics in mothers of affected multiples, and by the
association of an increased risk of recurrence with a short term of antibiotics [aOR 4.2 (1.3-14.2),
P=0.02]. Identical GBS serotypes in both recurrent infections and concurrently infected multiples
might indicate a failed microbiome integration of GBS strains that are generally regarded as
commensals in healthy infants. The dynamics of recurrent GBS infections or concurrent infections
in multiples suggest individual patterns of exposure and fluctuations in host immunity, causing
failure of natural niche occupation.Keywords: group B Streptococcus, late-onset sepsis, microbiome, multiples, recurrenceINTRODUCTION
Group B streptococcus (GBS) is a leading cause of sepsis and
meningitis in young infants worldwide (1). Globally in 2015, over
300 000 cases of invasive GBS disease (iGBS) caused 90 000 deaths
in infants < 90 days of age (2) and neurodevelopmental impairment
in over 10 000 children (3). IGBS is divided into early-onset sepsis
(EOS), with disease onset – depending on the definition – either in
the first 3 or 6 days, and late-onset sepsis (LOS) occurring thereafter
and before day 90. Maternal GBS colonization can lead to EOS via
vertical transmission at or before birth through ruptured
membranes (4). Many countries have reported a reduction in the
incidence of EOS after introducing administration of intrapartum
intravenous antibiotics (IAP) to women at risk of transmitting GBS
to their newborns (5, 6).
In contrast, the understanding of transmission and risk
factors for LOS is still incomplete. Prematurity and maternal
colonization increase the risk of LOS (7). In healthy infants,
mother to infant transmission of GBS can continue for weeks
after delivery (8). Neonatal colonization patterns matter, since
colonization may precede invasive infection (9).
The host-microbiome interactions are highly dynamic in the
first months of life (10). IAP has been shown to alter the
composition of the infant gut microbiota (11–13). It is
therefore conceivable that early distortions of the host-
commensal adaptation, mediated by perinatal antibiotic
exposure, may contribute to the pathogenesis of LOS. Indeed,
several studies have reported an increase in GBS LOS after
implementation of IAP, although this remains a controversial
issue (14–16).
Two particularly instructive entities of iGBS are those
occurring in infants of multiple births and those with recurrent.frontiersin.org 2episodes. The increased risk of multiple pregnancies for preterm
delivery and adverse outcomes in general is well established (17),
yet uncertainty exists about the specific association with iGBS. In
part due to the lack in understanding of disease pathogenesis,
there is no consensus about the management of the
asymptomatic sibling of an iGBS case from a multiple birth
(18). Additionally, the mechanisms underlying recurrent disease
are not fully understood. Prematurity, persistent mucosal
colonization and contaminated breast milk have been proposed
as risk factors (19). Since the shared (multiples) or fixed
(recurrence) genetic and environmental conditions may shed
some light on iGBS pathogenesis, this study analyzed cases in
multiples or with recurrence. From this analysis and review of
published GBS cases, we derive a model for LOS pathogenesis to
identify the infant at risk.METHODS
Study Design
UK and Ireland: Enhanced national surveillance of iGBS in
infants under three months of age in the UK and Republic of
Ireland (UKROI) was conducted between April 1, 2014, and
April 30, 2015. Data were collected through the British Paediatric
Surveillance Unit together with laboratories in England, Wales,
Scotland, Northern Ireland and Ireland. Serotyping using latex
agglutination and multilocus sequence typing (MLST) was
performed by Public Health England and the Irish Meningitis
and Sepsis Reference Laboratory. The study was approved by the
South East Coast– Brighton and Sussex Research Ethics
Committee (REC reference: 13/LO/1912; IRAS Project ID:
137959). The detailed methodology has been published (20).June 2021 | Volume 12 | Article 617925
Freudenhammer et al. iGBS With Recurrence and in MultiplesGermany and Switzerland: Medical centers from the German
Neonatal Network (GNN), consisting of 65 sites, were asked for
GBS LOS cases from 2008-2020 with a recurrent course or with
more than one affected multiple. This was complemented by an
e-mail request to 120 additional medical centers with NICUs in
Germany and Switzerland. Data were collected via data entry
forms. Data collection was approved by the ethics committee of
Freiburg University (Nr. 207/20).
Study Definitions
iGBS: EOS (day 0-3), LOS (day 4-89), or very-LOS (>90 days) with
GBS isolation from a normally sterile body site (blood, CSF). The
narrow EOS definition was chosen, since > 90% of cases in the first
week of life occur in this time frame. One episode of culture
negative sepsis was included because it was highly suggestive of
GBS LOS (clinical sepsis with consistent laboratory abnormalities,
isolation of GBS from infant’s oropharynx, a concurrent episode of
culture-positive GBS sepsis in the sibling and subsequent culture-
positive relapse of iGBS).
Index case: The first infant among multiples with iGBS.
Recurrent iGBS: New episode of clinical illness in an infant
associated with the isolation of GBS from a sterile site occurring
after the completion of the therapy for the first occurrence.
GBS colonization in infants: Positive oropharyngeal, ear or
rectal swab or gastric aspirate by culture or PCR.
Interval between two recurrent iGBS episodes: Days between
completion of antibiotics and onset of subsequent iGBS.
Duration of antibiotic treatment: Duration of the antibiotic
treatment of iGBS (penicillins or third generation cephalosporins).
Short course of antibiotic treatment: Treatment <10 days (21).
Statistical Analysis
Continuous variables were presented as median and range and
categorical data as numbers and percentages. Student’s t test or
the Mann–Whitney U test and x2 test or Fisher’s exact test were
used to compare continuous and categorical variables between
groups. A univariable regression analysis was used to estimate
associations with recurrent GBS infections in the UKROI cohort,
after removing all the cases that died after the first GBS episode.
Missing data were removed from the analysis. P value < 0.05 was
considered significant. A multivariable model was produced
using penalized regression to alleviate problems of accuracy
associated with the small size of the database. Akaike’s
Information Criteria (AIC) were used for model selection.
Analyses were performed using STATA and R software.
Literature Review of Cases
With iGBS Recurrence
Medline and Embase were searched via Ovid from 1974 - 03/
2020 for terms “Streptococcus agalactiae”, “group B strep*”,
“strep* agalact*”, “GBS”, “double or recur* or episodes or
relaps* or consecutive* or twice or two or three or four or five
or repet*”, “Infant, Newborn/”, “newborn*”, “neonat*, “infant*
adj4 (week* or day* or month* or premature or full term or
postmature or preterm). Additional studies were identified in
references of articles. Two cases in the current case study were
previously reported and excluded from the review (22, 23).Frontiers in Immunology | www.frontiersin.org 3RESULTS
GBS in Infants From Multiple Births
UKROI Cohort
Demographic and Clinical Characteristics
A total of 41 iGBS cases in infants from 35 multiple birth
pregnancies were identified, including six infant pairs in which
both twins developed iGBS (17%) (Table 1A). Twelve infants
from ten twin pairs had EOS, of which in two twin pairs (20%)
both infants developed EOS. The median gestational age (GA) of
twins with one sibling affected by GBS EOS was 35 (range 23-38)
weeks. LOS was diagnosed in 29 infants from 25 twin pairs, of
which in four twin pairs (16%) both infants developed iGBS.
Based on a LOS incidence of 0.37 per 1000 live births in this
population (20), the risk for LOS in a child from a multiple
gestation with an already affected sibling was over 400 times
higher. Comparison of the multiples with one versus two affected
infants revealed no significant differences in GA (median 32
weeks for both groups) or birth weight (median 1620 (860-3560)
g vs. 1685 (1070-2810) g). Median age at onset of GBS LOS was
42 (7- 86) days if one, and 27 (4- 54) days, if two infants were
affected. The median interval in onset of disease between siblings
was 2.5 (0- 18) days.
GBS sero- and sequence-typing revealed serotype III/ST-17 in
all three tested twin sets with both infants affected by LOS and in
5/12 (42%) isolates from twin cases with only one infant affected,
the rest accounted for serotypes III/ST-19 (n=2), Ia/ST-23 (n=4)
and VI/ST 17 (n=1). The median treatment duration was 14 (7-
32) days for sepsis and 14.5 (14-21) days for meningitis.
Demographic and Clinical Characteristics
Twin infants had a lower birth weight (median 1828 vs 3230 g,
P < 0.001) were more often born prematurely (85% vs 24%, P <
0.001), and developed iGBS significantly later (median 25 days vs
1 day, P < 0.001) than singletons (Table S1). The relapse rate was
similar (2.4% vs 1.7%, P = 0.5).
Demographic and Clinical Characteristics
Data on the management of the asymptomatic twin sibling of an
index case were available for 12 twin pairs. Eight infants were
clinically evaluated and antibiotics were not started, two of these
developed iGBS. In four cases antibiotic treatment was
preemptively administered to the second twin and stopped
after confirmation of negative cultures.German/Swiss Cohort
Demographic and Clinical Characteristics
Seven sets of twins and two sets of triplets, a total of 20 infants,
with GBS LOS were identified (Table 1B). One twin set showed
iGBS recurrence in both infants, leading to a total of 22 LOS
episodes in these multiples. All infants were born prematurely,
the median GA at birth was 31 (25-36) weeks. 7/20 infants (35%)
were low birth weight (<2500 g, LBW) and 13/20 (65%) very low
birth weight (<1500 g, VLBW). 11 (55%) infants were male. 4/9
pregnancies were di/trizygotic, 1/9 monozygotic, 2/9 were
identified as dichorionic/diamniotic, for two pregnancies the
data were not available. GBS cultures were negative in allJune 2021 | Volume 12 | Article 617925









N/A N/A 21 N/A
N/A N/A N/A N/A
III 17 14 N/A
III 17 14 N/A
N/A N/A 7 N/A
N/A N/A 7 N/A
V 1 N/A pA
N/A N/A 7 N/A
III NA 14 SM
III 17 21 SM
N/A N/A 7 SM
N/A N/A 14 SM
III 19 10 CE
N/A N/A 10 CE
III 19 N/A CE
N/A N/A N/A N/A
N/A N/A 14 N/A
VI 17 N/A N/A
III 17 21 N/A
N/A N/A 28 N/A
Ia 23 14 N/A
N/A N/A 14 pA
III 17 21 CE
N/A N/A 14 N/A
N/A N/A 15 N/A
N/A N/A 32 N/A
III 17 14 N/A
Ia 23 7 N/A
III 17 21 CE
III 17 15 pA
Ia 23 14 N/A
Ia 23 8 CE
N/A N/A 21 pA
III 17 10 NpA
III 17 14 NpA
III 17 14 N/A
III 17 14 N/A
III 17 21 N/A
III 17 21 N/A Y
N/A N/A 14 NpA
N/A N/A 14 NpA































































EOS - only one
sibling with iGBS
1 35 M 2650 N V neg N 0 P B
2 23 M 610 Y V N/A N 1 S B
3 38 M 3425 N V neg N 1 P B
4 36 M 2030 N V neg N 3 M B/CSF
5 39 M 2700 N V pos N 0 S B
6 36 F 2110 Y CS neg N/A 0 S B
7 33 M 1875 Y CS neg N 0 S B
8 35 F 2272 N V neg N 1 S B
EOS - all siblings
with iGBS
9a 36 M N/A N V neg N 1 S B
9b 36 F N/A N V neg N 1 M B/CSF
10a 33 F 1760 N CS neg Y 0 S B
10b 33 M 1870 N CS neg Y 0 M B/CSF
LOS - only one
sibling with iGBS
11 26 M 1060 N/A N/A N/A N/A 80 S B
12 37 M 3140 N/A N/A N/A N/A 53 S B
13 34 M 2040 N/A N/A N/A N/A 42 S B
14 30 F 1440 N/A N/A N/A N/A 85 S B
15 32 M 1550 N/A N/A N/A N/A 72 S B
16 26 M 940 N/A N/A N/A N/A 49 S B
17 34 F 2150 N/A N/A N/A N/A 31 M B/CSF
18 34 F 1690 N/A N/A N/A N/A 35 S B
19 36 F 2305 N/A N/A N/A N/A 7 M B/CSF
20 32 M 1150 N/A N/A N/A N/A 21 S B
21 37 F 2780 N/A N/A N/A N/A 52 M B/CSF
22 36 F 1785 N/A N/A N/A N/A 86 S B
23 25 M 860 N/A N/A N/A N/A 46 S B
24 38 F 3560 N/A N/A N/A N/A 70 S B
25 28 F 1115 N/A N/A N/A N/A 20 S B
26 32 M 1940 N/A N/A N/A N/A 42 S B
27 35 F N/A N/A N/A N/A N/A 35 S B
28 34 M 2360 N/A N/A N/A N/A 32 M B/CSF
29 27 F 890 N/A N/A N/A N/A 66 M B/CSF
30 30 F 1450 N/A N/A N/A N/A 17 S B
31 29 F 1095 N/A N/A N/A N/A 25 M B/CSF
LOS - all siblings
with iGBS
32a 38 F 2620 N CS neg N 5 S B
32b 38 M 2810 N CS neg N 4 M B/CSF
33a 32 M 1750 N/A N/A N/A N/A 31 M B/CSF
33b 32 M 2005 N/A N/A N/A N/A 13 S B
34a 30 M 1620 N/A N/A N/A N/A 50 S B
34b 30 M 1070 N/A N/A N/A N/A 54 M B/CSF
35a 33 F 1520 N/A N/A N/A N/A 30 S B
35b 33 F 1350 N/A N/A N/A N/A 24 S B
ABX, antibiotics; B, Blood; CE, clinical evaluation; CS, ceasarean section; CSF, cerebrospinal fluid; S, sepsis; M, meningitis; NpA, no prophylactic ABX; P, pneumonia;
cultures, SM Simultaneous occurrence of GBS infection; V vaginal delivery.
1Infants from the same family are indicated with the same number plus a,b,c.S
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Frontiers in Immunology | www.frontiersin.org 5mothers in whom antenatal maternal screening was performed
(7/9 mothers). 7/9 mothers received perinatal antibiotics
(indications: premature rupture of membranes, impending
premature birth, suspected chorioamnionitis, cesarean section).
The median age at onset of (first) GBS LOS was 48 (11- 118)
days. The median interval of LOS onset between affected siblings
was 5.5 (0-18) days. GBS grew in blood culture in 20 (91%), and
in CSF-culture in five (23%) cases. Serotyping was performed in
7/20 children: serotype III was identified in four children, and
serotype V in three. The isolates from twins were all of the same
serotype and sequence type. Breast milk was tested in six women:
three were positive for GBS by culture, one by PCR only, and two
were negative. Two women were not breastfeeding when iGBS
occurred in their infants. The median duration of antibiotic
treatment for GBS bacteremia was 14 (10-19) days and 20 (14-
21) days for meningitis. 10/16 infants with detailed medical
records received at least one course of antibiotics prior to onset of
iGBS; four of them for more than seven days. In five children
hypogammaglobulinemia was detected and normalization was
documented in two children. Recurrence of GBS LOS occurred
in four children (25%).
Recurrent GBS Disease
UKROI Cohort
Demographic and Clinical Characteristics
Twelve cases of recurrent iGBS were identified, accounting for
1.4% (12/856) of all infants with iGBS reported that year (20)
(Table 2). Eight (67%) infants were born prematurely, and five
(42%) infants were of very low birth weight (<1500 g). Ten (83%)
infants were male and one (8%) infant was from a twin
pregnancy. Median age at the onset of the first iGBS episode
was 11 (0- 73) days. Two (17%) infants had EOS and 10 (83%)
LOS as the first iGBS episode. Blood culture was positive in all
cases. In two (17%) infants GBS was additionally identified in the
CSF. The median duration of antibiotic therapy for the first
episode was seven (5- 14) days. Recurrence of iGBS occurred at a
median age of 39.5 (23- 84) days. The interval from completion
of initial therapy to onset of the second episode was 13 (5-75)
days. In the second episode all infants had a positive blood
culture and five (42%) had also a positive CSF for GBS. The
median duration of antibiotic therapy for the second episode was
21 (14-42) days. GBS capsular serotyping was performed in 17
isolates from 11 (92%) cases. Serotype III was the most
commonly isolated serotype (n=7, 64%), followed by Ia, Ib and
V, each identified in one (9%) infant. In eight (67%) cases isolates
from both episodes were available with identical serotypes in
seven out of these eight cases (88%). MLST sequencing was
performed in 13 isolates from seven (58%) cases and identified
ST-17 in four (57%) cases.
Risk Factors for GBS Recurrence
A univariable logistic regression showed that VLBW [OR 6.8
(1.9-22.0), P = 0.001], preterm birth [OR 5.6 (1.7-21.4), P =
0.005], a short course of antibiotics [OR 3.2 (1.0-10.9), P = 0.04]
and male sex [OR 4.4 (1.1-28.7), P = 0.05] were associated with
increased risk of GBS recurrence (Table 3, Table S2). When the
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Freudenhammer et al. iGBS With Recurrence and in Multiplesmultivariate penalized logistic regression model, the association
of GBS recurrence with VLBW [OR 9.7 (2.8-33.3), P < 0.001] and
a short course of antibiotics [OR 4.2 (1.3-14.2), P = 0.02]
remained significant (Tables 3 and S2).
German/Swiss Case Series
Demographic and Clinical Characteristics
Thirteen cases of recurrent iGBS were reported from ten centers
in Germany and Switzerland within a 12-year period (Table 2).
Nine (69%) infants were born prematurely (median 32, range 23-
41 weeks) and six (46%) were VLBW. Nine (69%) infants were
female and five (38%) infants were from a twin pregnancy.
Median age at the onset of the first iGBS was 28 (1-150) days.
Three (23%) infants had EOS. GBS was isolated in the blood
culture in all 13 cases. Three out of nine cases with a lumbar
puncture had a concurrent meningitis. The first episode was
treated with antibiotics for 14 (7-21) days. Recurrence of iGBS
occurred at a median age of 44 (24-64) days. The median intervalFrontiers in Immunology | www.frontiersin.org 6from completion of initial therapy to onset of second episode was
nine (3-37) days. In three cases (25%) GBS grew in the CSF
culture in the second episode in addition to the blood culture.
The median duration of antibiotic therapy for the second episode
was 14 (9-19) days. GBS capsular serotyping was performed in
one (8%) case (serotype III ST-17). Breast milk samples from
eight (62%) out of 13 tested breastfeeding women revealed a
positive result (by culture or PCR) in five women during the first
or second episode. In six (50%) out of 12 cases, where data were
reported, breastfeeding was stopped after the first or second iGBS
episode and restarted after antibiotics for GBS “eradication” in
two of these six cases. In one further case breast milk
was pasteurized.
Four infants were treated with antibiotics with the aim to
decrease GBS colonization or prevent further bacterial infections
until immunological investigations were completed. In nine
infants, where immunological tests were done, two were
diagnosed with transient hypogammaglobulinemia, one hadTABLE 2 | Clinical features of cases of recurrent GBS disease.


















Germany 1 F 565 23 CS 1 B 10 48 B 12 124 B 21 N/A N/A pos pos neg Yes N no
Germany 2 F 670 25 CS 41 B 14 84 B 21 – – – N/A N/A pos neg neg No* ^ no
Germany 3 F 1230 27 V 46 B 7 62 B 10 – – – N/A N/A neg neg pos Yes** N no
Germany 4 F 590 23 N/A 150 B 9 166 B/
CSF
42 – – – N/A N/A neg N/A pos Yes** ^^ DD
Germany 5 F 1732 32 CS 35 B 14 64 B 14 – – – N/A N/A N/A neg pos Yes N no
Germany 6 F 1470 32 CS 28 B/
CSF
21 63 B 14 – – – N/A N/A N/A N/A pos Yes N no
Germany 7 F 2890 39 V 10 B 10 25 B 14 – – – N/A N/A N/A neg neg No N/A no
Germany 8 F 4320 37 V 1 B 15 25 B/
CSF
14 – – – N/A N/A neg pos N/A No N/A no
Germany 9 M 3020 37 CS 1 B 14 21 B 14 – – – N/A N/A pos pos N/A No N/A no
Germany 10 M 3020 35 V 20 B/
CSF
15 60 B 14 – – – N/A N/A pos neg N/A No N/A no
Germany 11 F 4190 41 V 3 B 7 24 B 14 – – – N/A N/A N/A neg N/A No ^^^ no




19 – – – III 17 neg pos pos Yes N no
Germany 13 N/A 1920 31 CS 47 B 10 60 B 9 – – – N/A N/A N/A N/A N/A N/A ^^ no
UKROI 14 F 1082 27 N/A 39 B 10 59 B 14 – – – Ia N/A N/A N/A N/A N/A N/A N/A
UKROI 15 M 3770 39 V 0 B 7 23 B 14 – – – III 17 N/A neg N/A N/A N/A N/A
UKROI 16 M 3350 42 N/A 11 B 7 25 B 40 – – – III 17 N/A N/A N/A N/A N/A N/A
UKROI 17 M 2020 31 N/A 73 B 5 84 B 42 – – – N/A N/A N/A N/A N/A N/A N/A N/A
UKROI 18 M 770 23 N/A 1 B 9 30 B/
CSF
21 – – – Ib new N/A pos N/A N/A N/A D




21 – – – V/III 17 N/A N/A N/A N/A N/A N/A
UKROI 20 M 1490 29 N/A 37 B 10 59 B/
CSF
21 – – – III 17 N/A N/A N/A N/A N/A N/A




21 – – – III 17 N/A N/A N/A N/A N/A N/A
UKROI 22 M 3900 41 N/A 16 B 7 28 B 14 – – – III N/A N/A N/A N/A N/A N/A N/A
UKROI 23 M 600 23 N/A 0 B 7 82 B N/A – – – III N/A N/A N/A N/A N/A N/A N/A
UKROI 24 M 1620 31 N/A 8 B 14 41 B 14 69 B 14 III 23 N/A N/A N/A N/A N/A N/A
UKROI 25 F 1790 32 CS 0 B 10 23 B/
CSF
21 – – – V N/A N/A N/A N/A N/A N/A N/AJune 2021 | Volume 12 | Article 61AN, Abnormal; C, Cellulitis; CS, Ceasarean section; D, Death; DD, Developmental delay; Imm, Immunology; Me, Meningitis; N, Normal; N/A, Not available; S, Sepsis; Seq., Sequelae; V,
Vaginal delivery, *Pasteurized, **Temporary (restarted after maternal decolonization), ^: lack of Memory B cells and neutropenia, ^^: transient hypogammaglobulinemia, ^^^: reduced
CH50 activity (<10%).7925
Freudenhammer et al. iGBS With Recurrence and in Multiplesreduced complement activity, and one had absent memory B
cells and neutropenia.
Literature Review on Recurrent iGBS
Demographic and Clinical Characteristics
We identified 44 case reports or case series of GBS recurrence in
84 infants between 1976 and 2019 (Table S3). Fourteen infants
(24%) were twins or triplets. 64 infants (76%) had bacteremia, 16
(19%) had meningitis with bacteremia, three (4%) only
meningitis and six infants (7%) had cellulitis (5 with a positive
blood culture). The median age at onset of the first episode was
15 (0-120) days. Antibiotics were administered for 10 (7-28) days
for the initial episode. Of the infants, in whom information was
available 42/74 (57%) were preterm, 30/50 (60%) were males, 28/
42 (67%) were born vaginally.
Recurrence of GBS disease occurred at a median age of 40 (8-
141) days. The median interval from completion of antibiotic
therapy to onset of second episode was eight (0-54) days. 64
infants (76%) had recurrent bacteremia, 16 (19%) had meningitis
with bacteremia, and three (4%) meningitis without bacteremia.
Antimicrobial therapy for the second episode of iGBS was
administered for 14 (10-42 days) days. A third episode of GBS
disease occurred in 11 infants (13%) at a median age of 61.5 (32-
120) days. Capsular serotyping was performed in 56 isolates (67%)
with serotype III in 40 cases (71%). The hypervirulent clone ST-17
was found in five cases where MLST results were reported.
31 breast milk samples were tested by culture or PCR and were
positive for GBS in 25 cases (81%). Mastitis was reported by eight
women (32%). GBS serotypes of the 11 serotyped breast milk
samples were identical to those found in the infants. In 13 (52%)
cases breastfeeding was ceased. 14 mothers were treated with
antibiotics for mastitis or GBS decolonization. Following
treatment, the breast milk of six out of seven (86%) women did
not reveal GBS (culture or PCR). 12 infants were treated withFrontiers in Immunology | www.frontiersin.org 7antibiotics to decrease GBS colonization. After treatment, four out
of six (67%) infants had a negative GBS swab, in one case after a
second course of rifampicin. Immunological investigations revealed
transient hypogammaglobulinemia in three infants.
Comparison of the Three Cohorts With Recurrence
Recurrent iGBS cases from the UKROI, German/Swiss and
literature cohort were largely similar (Figure S1). Fewer infants
from the German/Swiss case series were male as compared to
UKROI (25% vs 83%, P = 0.01) and the literature (25% vs 60%, P =
0.05). Antibiotic treatment for the first episode of iGBS was shorter
in UKROI (median 7 vs 14 days in German/Swiss cases, P = 0.01; vs
12.5 days in literature, P < 0.001). Yet, antibiotic treatment for the
second episode of iGBS was longer in UKROI (median 21 vs 14
days in German/Swiss cases, P = 0.002; vs 14 days in literature, P =
0.06). Meningitis in the second GBS episode was more common in
UKROI compared to literature (42% vs 13%, P = 0.03).
Summary of Recurrent Cases and
iGBS in Multiples
Combining the UKROI and German/Swiss cohorts reveals that
infants with recurrent iGBS did not differ from multiples, in
which more than one sibling developed iGBS with respect to
gestational age, birth weight and age of LOS onset (Table 4).DISCUSSION
Cases of iGBS in infants of multiple births and those with
recurrence provide intriguing insights as to how a highly virulent
bacterial species adapts, or fails to do so, to the individual
mucocutaneous interface as well as to the intra-familial host-
commensal community. Birth constitutes a major microbial
seeding event. Subsequently, a highly dynamic network develops,TABLE 3 | Univariable and Multivariable Logistic Regression analysis of recurrent GBS disease (UKROI).
Univariable Multivariable
OR (95% CI) P value OR (95% CI) P value
Antibiotic course <10 d 3.2 (1.0-10.9) 0.04 4.2 (1.3-18.0) 0.02
Very Low Birth Weight (<1500 g) 6.8 (1.9-22.0) 0.001 9.7 (2.8-33.3) <0.001
Preterm Birth (<37 weeks) 5.6 (1.7-21.4) 0.005





Age at onset of 1st iGBS in
days, median (IQR)
Infants with ATX before




Multiplesb 32 (5) 1495 (721) 33 (40)c NA 4.5 (6.5)
UKROI (n=12) 33 (4) 1755 (426) 27 (25)c NA 2.5 (5)
German/Swiss (n=20) 31 (6) 1220 (742.5) 48 (58)c 62.5c 5.5 (6)
Recurrence 31 (10) 1732 (1938) 35 (30)c NA 12.5 (12)
UKROI (n=12) 31 (11) 1705 (2121) 21 (26.5)c NA 13 (11)
German/Swiss (n=13) 32 (10) 1732 (1895) 40 (19)c 56 c 9 (8)aMultiples: Interval between siblings developing iGBS. Recurrence: Interval between completion of antibiotics for the first iGBS and onset of second iGBS for the same infant.
bMultiple sets >1 sibling affected by iGBS.617925
Freudenhammer et al. iGBS With Recurrence and in Multipleswhere microorganisms as well as immunologically important
macromolecules are exchanged between family members. This
goes in parallel with neonatal immune development. Normally,
GBS reaches its niche without health implications for its infant host.
Up to 20% healthy infants are colonized with GBS at two months of
age (8) and iGBS occurs in less than 1% of colonized infants.
Recurrence rate is low [1.5% in our cohort in keeping with previous
reports (24)], suggesting that iGBS is usually a “singular accident”
rather than the result of immune problems in handling this
organism. In contrast, it might lead to acquisition of host
resistance, since further GBS contacts via the individual flora or
family members are likely to occur and in general remain
without consequences.
Our study elucidates what might go wrong in this process. In
multiples, a sibling with iGBS is a major risk factor, increasing the
incidence of iGBS in the other sibling to 17%, i.e. tenfold higher as
compared to the risk attributed to maternal colonization (25). The
mechanisms of GBS transmission in LOS are still unclear. The main
hypotheses are that acute transmissionoccurs after exposure toahigh
bacterial load (e.g. via breast milk) and endogenous translocation
following mucosal colonization (Figure 1). Our data provide
evidence supporting both scenarios. Simultaneous onset of iGBS in
siblings within 48 hours, occurring many weeks after birth, is highly
suggestive of an acute infection of both siblings from an external
source, e.g. the mother. Alternatively, the infecting GBS clone may
have changed its phenotype from “colonizing” to “invasive” andmay
be acutely transferred from one infant to the other, e.g. via the
maternal breast.On the other hand, a long interval of up to 18days inFrontiers in Immunology | www.frontiersin.org 8LOS onset between twin siblings suggests fluctuations in the
individual host immunity rather than an acute infection.
Prematurity is characterized by disturbances of microbiome
development, associated with frequent use of antibiotics, formula
feeding and reduced contact with the maternal microbiome. It is
tempting to speculate that these factors might disturb the adaptation
of GBS to its neonatal host environment. Overall, maternal and
subsequent neonatal GBS colonization are major risk factors for
iGBS (7). Notably, in the German/Swiss multiple study, maternal
antenatal rectovaginal swabs (if available) were all negative for GBS.
Nearly all these women received antibiotics prior to birth, which
probably reduced short term colonization with GBS, but also caused
alterations of infant intestinal composition, such as a reduction in
Bifidobacteria or an increase of Firmicutes species (12, 13).
Accordingly, “natural” exposure to the adapted maternal GBS
strain may have been missing in these infants very early in life.
Moreover, antibiotics may alter bacterial virulence, which is best
exemplified by the emergence of the hypervirulent GBS type III
ST17 clone under tetracycline treatment pressure (26). According to
amodel where high GBS virulence promotes recurrence and parallel
infections in multiples, ST-17 was, when molecular typing was
performed, the most common clone isolated in our cohorts. The
perinatal use of antibiotics may also directly disturb the
development of host immunity, since antibiotics impact on
neonatal myeloid cell homeostasis that provides resistance against
sepsis (27). The observation that increased use of intrapartum
antibiotics lowers the incidence of EOS, but may increase that of
LOS is in concordance with this notion (14–16).FIGURE 1 | Model of pathogenesis of (recurrent) Group B streptococcus late-onset disease. Several factors (boxes) impact on the outcome of postnatal contact of
the neonate with GBS: uneventful integration into microbiome vs. invasive GBS infection (Figure was created using BioRender.com).June 2021 | Volume 12 | Article 617925
Freudenhammer et al. iGBS With Recurrence and in MultiplesInvasive infections with potential pathogens like GBS with
recurrence and in siblings are compatible with inherited immune
aberrations. However, iGBS is usually a sporadic event and rarely
uncovers genetic immunodeficiency (10, 28). Moreover,
monozygosity did not stand out as a risk factor in our
collection or previous reports (29). However, preterm birth is
associated with various alterations of host resistance, e.g. low
transplacental antibody transfer (30). Yet, immune functions do
not develop in a linear fashion postnatally. For example, induced
monocyte and T-cell activation is partly higher, but neutrophil
function is impaired in preterm as compared to term infants and
adults (31). Occasionally associated hypogammaglobulinemia,
complement deficiency and neutropenia often reflect transient
alterations rather than inborn errors of immunity.
Breast milk contributes to the protection against infections in
various ways (32), but it is also a potential source of infection (33).
GBS strains detected in breast milk were of the same serotype as
the invasive strains isolated in the infants in our cohort, in case
information was available. An alternative hypothesis is that
mammary ducts become colonized by contact with the oral
mucosa of the infant and GBS in the breast milk may just be a
biomarker of the “family microbiome” (19). In general, GBS can
persist at mucosal surfaces, and thus as a GBS source, even after
adequate parenteral therapy (34). This concurs with the
observation that the second episode is typically caused by the
same serotype as the first, although this information was not
available for all cases. Yet repeated translocation from the natural
ecological habitat to the blood stream must be discriminated from
failed eradication of truly infective foci by insufficient antibiotic
treatment. Thus, the association between shorter antibiotic
treatments course and increased recurrence risk, and recurrences
within a week after treatment in a third of infants may highlight a
subgroup of insufficiently treated cases rather than being
paradigmatic for recurrence. The proportion of infants with
recurrent iGBS disease that received a short course of antibiotics
was disproportionately high in UKROI compared to the German/
Swiss case series and the existing literature (Figure S1). Moreover,
this finding is in disagreement with a recent study that did not
show any difference in recurrence rate between shortened (≤8
days) and prolonged (>8 days) course of antibiotics among infants
with uncomplicated iGBS disease. Overall, the risk of recurrence in
uncomplicated iGBS is low, even if antibiotics are used for less
than 8 days (35).Frontiers in Immunology | www.frontiersin.org 9How to Prevent Infection of the
Asymptomatic Sibling and Recurrence in
GBS Disease
Current recommendations of 10 days of intravenous (IV)
antibiotics for GBS bacteremia and at least 14 days for
meningitis should be adhered to (21). However, following this
standard did not prevent early recurrence in several cases in our
study. Moreover, and as outlined above, antibiotics in the perinatal
area have undisputed costs including an increased susceptibility to
sepsis. Thus, empiric antibiotic treatment in this vulnerable phase
should be limited to well defined standards of antibiotic
stewardship, in particular to early discontinuation if sepsis is
ruled out.
The management of twins of iGBS cases has been the subject of
several papers and guidelines (15, 18, 21, 36). Current NICE
guidelines recommend antibiotic treatment of the other
multiple(s) in case of confirmed or suspected EOS, however, no
recommendations for LOS are provided (37). If a twin develops
GBS EOS, the iGBS risk for the other is up to 40% (25), typically
within the next 24h. The short interval in GBS sepsis cases between
siblings in our cohort may justify starting antibiotic treatment of the
other multiple(s) in case of confirmed or suspected EOS, however,
this remains a controversial issue. In any case, a careful clinical
observation for the next 24 h seems reasonable (15). In contrast the
interval in onset of LOS between siblings is highly variable, which
makes parent education important. Routine administration of
“prophylactic” antibiotics does not seem justified in LOS, given
the missing evidence for a therapeutic effect and the potential costs
for the host-microbiome interface (21, 36). Microbiologic
investigation of breast milk and, in case of positive culture,
antibiotic treatment of the mother seem appropriate in recurrent
iGBS or concurrent diseases in multiples, despite lacking evidence.
Additionally, probiotics may decrease the incidence of neonatal
sepsis in general (38), and experimental models suggest a positive
impact on GBS colonization (10, 39). Recommendations are
summarized in Table 5.CONCLUSIONS AND OUTLOOK
The dynamics of recurrent GBS infections or concurrent
infections in multiples suggest individual patterns of exposureTABLE 5 | Practical recommendations for investigations and management of the asymptomatic twin in case of invasive GBS disease in a multiple birth or with recurrent course.
The recommended length of antibiotic treatment is 10 days for bacteremia without focus and 14 days for uncomplicated meningitis. A longer course is recommended
when there is a complicated course.
When the sibling in a multiple birth has confirmed or suspected invasive GBS disease:
• using clinical judgement, consider starting antibiotic treatment of the other multiple(s) in case of confirmed or suspected EOS
• apply continuous clinical observation of the asymptomatic twin over min. 24H
• immediately start antibiotics with any sign of disease and consider stopping the antibiotics at 36 hours if the blood culture is negative, and the initial clinical suspicion
of infection was not strong, and the baby’s clinical condition is reassuring and the levels and trends of biomarkers (GBC, CRP, IL-6) are reassuring
• educate the parents about the increased risk for infection in the currently asymptomatic twin and recommend prompt consultation of a doctor in case of any signs or
symptoms
In case of recurrent GBS ID or concurrent GBS LOS in children of a multiple birth:
• Consider testing breast milk, discuss temporary cessation of breastfeeding or pasteurization of breast milk awaiting breast milk cultures
• If breast milk contamination is confirmed, offer eradication treatment with oral rifampicin for 5 days and retestingJune 2021 | Volume 12 | Article 617925
Freudenhammer et al. iGBS With Recurrence and in Multiplesand fluctuations in host immunity (Figure 1). As indicated by
the low interval of iGBS in affected multiples, GBS can –
probably clonally – deviate from its usually colonizing traits
and become highly invasive, spreading across inter-individual
boundaries. This occurs with remarkable frequency, i.e. in a sixth
of multiple births in which one infant has iGBS. Identical GBS
sero- and sequence types in recurrent cases and concurrently
infected multiples may indicate a “streptococcal niche” at
colonizing sites, which needs to be demarcated by the immune
system and by competing microbes to allow for GBS to become a
harmless, metabolically programmed colonizer. The necessary inter-
kingdom efforts to achieve lasting coexistence are reflected by the
relative long intervals between recurrent iGBS episodes in the affected
(preterm) infants,whousually rapidlydevelopdiseaseonce invasively
infected. Notably, risk factors for recurrence and simultaneous iGBS
inmultiples are overlapping, and iGBS inmultiples seems to be a risk
factor for recurrence. In order to better understand iGBS
pathogenesis, it is essential to delineate the risk of empirical
antibiotics, as well as the role of antibody-mediated and mucosal
cellular immunity in newborn infants in unavoidable contact with
GBSandotherpotential pathogens. It is an intriguingperspective that
the improved understanding of host-microbe interface development,
including the resolutionof the “streptococcalniche”, will allow for the
development of designer probiotics capable of improving health in
the fragile neonatal period.DATA AVAILABILITY STATEMENT
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